To hear about similar clinical trials, please enter your email below
Trial Title:
Design and Testing of a Web-Based Tool for the Improvement of End-of-Life Planning in Patients With Advanced Cancer
NCT ID:
NCT05564468
Condition:
Hematopoietic and Lymphoid System Neoplasm
Locally Advanced Malignant Solid Neoplasm
Metastatic Malignant Solid Neoplasm
Conditions: Official terms:
Neoplasms
Study type:
Interventional
Study phase:
N/A
Overall status:
Recruiting
Study design:
Allocation:
Randomized
Intervention model:
Parallel Assignment
Primary purpose:
Supportive Care
Masking:
Double (Investigator, Outcomes Assessor)
Intervention:
Intervention type:
Other
Intervention name:
Best Practice
Description:
Receive standard of care
Arm group label:
Group II (standard of care)
Other name:
standard of care
Other name:
standard therapy
Intervention type:
Other
Intervention name:
Internet-Based Intervention
Description:
Receive Peacefully's end-of-life planning program
Arm group label:
Group I (Peacefully's)
Intervention type:
Other
Intervention name:
Questionnaire Administration
Description:
Ancillary studies
Arm group label:
Group I (Peacefully's)
Arm group label:
Group II (standard of care)
Summary:
This clinical trial examines a web-based tool, in partnership with Peacefully, Inc,
designed to improve end-of-life planning among patients with advanced cancers. This
program helps users prepare comprehensively for end-of-life (e.g., medical wishes, legal
estate planning, financial planning and transfer of accounts, legacy building, and
emotional support). It is expected that this web-based end-of-life planning program may
reduce distress and improve end-of-life preparation among advanced cancer patients.
Detailed description:
OUTLINE:
Patients are randomized to 1 of 2 groups and their engagement in end-of-life planning is
assessed at baseline and four weeks post-randomization.
Group I (intervention): Patients receive Peacefully's web-based tool to help with
end-of-life planning on day 7.
Group II (control): Patients receive standard of care.
After completion of study, patients are followed up at 4, 12, and 24 weeks
post-randomization.
Criteria for eligibility:
Criteria:
Inclusion Criteria:
- Diagnosis of poor prognosis advanced cancer defined as locally advanced or
metastatic cancer and/or disease progression following at least first line
chemotherapy
- Access to a computer or mobile device
- The ability to provide informed consent
Exclusion Criteria:
- Not fluent in English
- Severely cognitively impaired (as measured by Short Portable Mental Status
Questionnaire scores of < 6)
- Too ill or weak to complete the interviews (as judged by the interviewer)
Gender:
All
Minimum age:
18 Years
Maximum age:
N/A
Healthy volunteers:
No
Locations:
Facility:
Name:
Fred Hutch/University of Washington Cancer Consortium
Address:
City:
Seattle
Zip:
98109
Country:
United States
Status:
Recruiting
Contact:
Last name:
Megan J. Shen
Phone:
206-667-4172
Email:
mshen2@fredhutch.org
Investigator:
Last name:
Megan J. Shen
Email:
Principal Investigator
Start date:
May 21, 2024
Completion date:
July 31, 2025
Lead sponsor:
Agency:
Fred Hutchinson Cancer Center
Agency class:
Other
Collaborator:
Agency:
National Institute of Nursing Research (NINR)
Agency class:
NIH
Collaborator:
Agency:
Peacefully, Inc.
Agency class:
Other
Source:
Fred Hutchinson Cancer Center
Record processing date:
ClinicalTrials.gov processed this data on November 12, 2024
Source: ClinicalTrials.gov page:
https://clinicaltrials.gov/ct2/show/NCT05564468
